FDA Clears New Electrocardiogram Suite of Algorithms and Analytics
Geared toward ambulatory use, the HeartKey Rhythm suite reportedly offers enhanced signal clarity and rhythm detection algorithms.
While noise contamination has been an issue with electrocardiograms (ECGs), a newly FDA-cleared suite of ECG algorithms may bolster signal clarity and detection of cardiac conditions.
Featuring unique signal processing technology, the HeartKey Rhythm suite facilitates noise reduction and improved data quality with ECGs, according to B-Secur, the developer of HeartKey Rhythm.1 The company maintains that the HeartKey Rhythm suite provides an antidote for challenges with ECG interpretation, citing a 2020 survey in which 53 percent of clinicians noted difficulty with interpreting remote ECGs.2
Featuring unique signal processing technology, the FDA-cleared HeartKey Rhythm suite facilitates noise reduction and improved data quality with ECGs, according to B-Secur, the developer of HeartKey Rhythm. (Image courtesy of B-Secur.)
"There is an ever-increasing reliance on ECG data collected outside of a controlled clinical environment," said Adrian Condon, the chief technology officer and co-founder of B-Secur. "Our breakthrough FDA cleared product, HeartKey Rhythm, significantly improves the ECG signal processing and rhythm recognition of ambulatory devices and platforms."
The company added that on-chip solutions with the HeartKey Rhythm suite can be utilized for patient wearable devices, further facilitating timely care for common cardiac conditions.
References
1. B-Secur. B-Secur elevates proactive, efficient cardiac care with FSA-cleared HeartKey Rhythm solution. PR Newswire. Available at: https://www.prnewswire.com/news-releases/b-secur-elevates-proactive-efficient-cardiac-care-with-fda-cleared-heartkey-rhythm-solution-302236210.html?tc=eml_cleartime . Published September 3, 2024. Accessed September 5, 2024.
2. Ding EY, Svennberg E, Wurster C, et al. Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. Cardiovasc Digit Health J. 2020;1(1):21-29.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
